Bayer Acquires Remaining 25% Stake In JV With Zydus Lifesciences
Zydus Lifesciences Ltd. will exit a joint venture with the local arm of German pharma major Bayer AG, after selling its 25% stake for Rs 282 crore. The board approved entering into a share purchase agreement for sale and transfer of shares in Bayer Zydus Pharma Pvt. to Bayer Pharmaceuticals Pvt., according to an exchange filing on Thursday.
The transaction will not have material impact on the company and will be conducted within 10 days from the date of execution of the deal.
The two drugmakers started their joint venture in 2011 for sale and marketing of pharmaceutical products in India, with an aim to combine Zydus's strong local marketing, sales expertise and distribution reach with Bayer's global expertise in commercialising novel solutions.
Bayer Zydus Pharma has made available therapies in the areas of cardiovascular diseases, diabetes, women's health, ophthalmology and oncology in the country.
The joint venture agreement required Zydus Lifesciences to sell its stake after 13 years to either Bayer or its affiliates.
Shares of the Mumbai-based pharmaceutical companies closed 3.62% higher at Rs 988.1 apiece on Thursday, ahead of the announcement, as compared with a 0.17% advance in the benchmark BSE Sensex.
(Corrects an earlier version of the article that mistated Bayer Zydus Pharma as the manufacturer of Saridon and Alaspan)
-
We May Need Another Tukaram Mundhe To Fight Air Pollution | The Reason Why
Developers may install basic measures such as sprinklers and green nets, resume work, and continue violating rules when this equipment stops working.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.